Dr. Dong Liu, Ph.D., serves as our chief execute office (CEO) since 2015. Prior to founding Kind Pharmaceuticals, Dong was a project leader of Fibrogen and a senior pharmacologist at Merck. With over 10 years’ experience in both Pharma giant and innovative biotech, Dong has evolved to a seasoned scientist with expertise on pharmacology, PK, and toxicology. Dong was a research assistant professor at University of Rochester before entering industry. Dong holds a Ph.D. degree in pharmacology from China Marine University, and bachelor and master’s degree in Pharmacy in Shandong University in China. Dong received his postdoctoral training at Max-Planck-Institute of Psychiatry in Germany. Dong published multiple peer reviewed articles in Nature Medicine, Nature Neuroscience, Neuron, Circulation, etc.
Dr. Shaojiang Deng, Ph.D., is the Chief Scientific Officer (CSO) at Kind. He has rich and successful experience in organic synthesis (25+ years) and drug discovery, development, and manufacturing (15+ years), and has broad bench-to-bedside knowledge in drug industry. He held titles in research position from scientist to principal scientist at FibroGen (2004-2019) and was awarded several times for critical contributions at FibroGen. He conducted postdoctoral research at Harvard Medical School and UCSF (1999-2004). He obtained Ph.D. from Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences (1999); he is the recipient of multiple national and regional awards in China.
Dr. Qi Zhu, M.D., joined Kind as the Chief Medical Officer (CMO) and the member of board of directors in early 2019 with near 30 years’ extensive experience in global clinical drug development in the pharmaceutical industries. Before joining Kind, he was a senor medical officer at Baxalta/Shire, where he successfully led ONIVYDE® global clinical development and approvals. Prior to that, he was the Global Head of Clinical R&D in BMS MI and Lantheus (a BMS span-off) for over twelve years, where he was responsible for 6 pipelines’ development and 3 products’ life cyclic management. He managed about 80 protocols from phase I to phase IV; 4 NDA/sNDA/MAA and 3 IND submissions; and achieved 3 new approvals. Prior to joining BMS, Dr. Zhu was the Executive Clinical Director at ABR, a full service CRO, where he led execution of the clinical and regulatory affairs programs. Dr. Qi Zhu earned a M.D. degree from Suzhou University Medical School, China, and he completed his clinical post-doctoral training and clinical research fellowship at Schepens Eye Research Institute, MEEI and Harvard Medical School where he stayed on staff, as PI or co-PI, to focus on clinical research for new drug development, prior to transitioning to healthcare industry.
Dr. Yingping Jiang, Ph.D., joined Kind as Chief Biological Officer (CBO) in 2022 with nearly 30 years of extensive experience in antibody development in both biotech and pharmaceutical industries. Before joining Kind, she was Head of antibody development in Pliant Therapeutics, where she successfully led PLN-101325 to IND filing for DMD indication. Prior to that, Dr. Jiang was at ModMab Therapeutics, Cellerant Therapeutics, Trellis Bioscience and Berlex Biosciences, where she led multiple research teams and oversaw oncology, immunology and infectious disease programs from early target discovery to preclinical validation and IND submission. Dr. Jiang is a well-published scientist who earned her Ph.D. from NYU and did post-doctoral training at Tularik.